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dressed by measuring fibrinogen-erythrocyte 
unbinding forces by atomic force microsco-
py (AFM) based force spectroscopy.For the 
sake of comparison the measurements of 
the fibrinogen-erythrocyte interaction were 
always conducted in parallel with measure-
ments of the well known interaction of fi-
brinogen with platelets. It is worth of notice 
that the later interaction has been exten-
sively studied, but not by the methodology 
described here.
AFM is mainly an imaging technique, in which 
the surface of a sample is scanned, line by 
line, by the movement of a thin tip, mounted 
on a flexible cantilever (for a review see, [6]). 
The tip-sample repulsion at the atomic level, 
transduced by the cantilever deflection and 
by an optical lever mechanism, permits the 
association of a height value to each position 
on the x,y plan and, therefore, the reconsti-
tution of a pseudo-3D image of the sample 
surface. In addition to being used for imag-
ing, the AFM can also be used to quantify 
the interaction between the tip and a specific 
spot of the sample, taking advantage of the 
pico-Newton sensitivity of the method. This 
1. FIBRINOGEN-ERYTHROCYTE MEMBRANE 
INTERACTION
Upon bleeding due to the opening of a 
wound on a blood vessel, the coagulation 
process is triggered. The plasma protein 
fibrinogen builds up the scaffold for the 
blood clot formation, by polymerizing in a 
fibrin network and entrapping the blood 
cells. The main physiological receptor for 
fibrinogen is the platelet membrane in-
tegrin αIIbβ3. As fibrinogen has more than 
one integrin-binding site, it is able to simul-
taneously bind two platelets, bridging them 
and regulating blood hemostasis.
Beside the relevance of the fibrinogen-
platelet binding, it is also known that high 
plasma fibrinogen levels induce erythro-
cyte hyperaggregation [1-3], and that this 
increased aggregation constitutes a seri-
ous cardiovascular risk factor [4, 5]. This 
prompted us to study: (i) how does fibrino-
gen increase erythrocyte aggregation? (ii) Is 
there a specific receptor for fibrinogen on 
the erythrocyte membrane? (iii) Can this in-
teraction be modulated to reduce hyperag-
gregation? These three questions were ad-
ABSTRACT
Biological membranes are dynamic struc-
tures essential for several cellular phenom-
ena. The scope of the work of the Institute of 
Molecular Medicine (IMM) Biomembranes 
Unit is the study of biochemical and bio-
physical processes occurring at the mem-
brane level on human cells and on their 
viral and bacterial pathogens. On the viral 
context, we are primarily interested on HIV 
and dengue virus, and particularly on the 
two steps of their life cycle involving their 
interaction with host cell membranes: the 
viral entry into target cells and the assembly 
of new viral particles. A special focus will 
be given to the study of the role of biologi-
cal membranes on the mechanism of action 
of the HIV entry (membrane fusion) inhibi-
tors enfuvirtide and T-1249. We are also in-
volved in assessing the molecular basis of 
the activity of microbicides, such as rBPI21, 
that bind to specific components of bacte-
rial membranes. Additionally, our line of 
work on the binding of fibrinogen to erythro-
cytes, and its relevance as a cardiovascular 
risk factor will be presented. An approach to 
the latter problem by single-molecule force 
spectroscopy, using an atomic force micro-
scope (AFM), allowed the molecular recog-
nition, characterization and partial identifi-
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approach is usually termed “force spectros-
copy” (despite not being in fact a “spectros-
copy”, as it is not based on the interaction of 
radiation with matter!).
On the context of this study, we used iso-
lated human erythrocytes or platelets, in 
buffer, lightly adherent by electrostatic 
interactions to poly-L-lysine-treated glass 
slides. The force spectroscopy approach 
is based on the covalent attachment of 
fibrinogen molecules to the AFM silicon 
nitride tips, following methodologies pre-
viously applied to other proteins [7, 8]. Af-
ter this, we use the AFM to tap with the fi-
brinogen-functionalized tip on the surface 
of the blood cell (Figure 1) [9, 10]. In the 
situations in which the binding occurs, the 
additional force necessary to detach the 
tip (and the fibrinogen molecule) from the 
cell can be calculated, based on force vs. 
distance curves [11]. After performing and 
analyzing hundreds or thousands of these 
binding / unbinding curves, a frequency 
vs. rupture force histogram can be built 
up. The fitting using Gaussian functions 
of the histogram peaks allowed the deter-
mination of the force necessary to break a 
single fibrinogen-cell interaction, with ad-
ditional peaks corresponding to multiples 
of this value (Figure 2). The comparison of 
the results obtained by this methodology 
led us to a first surprise: The average force 
necessary to break the fibrinogen-eryth-
rocyte interaction (79 ± 3 pN) is lower but 
quite comparable with the force necessary 
to break the fibrinogen-platelet interaction 
(97 ± 2 pN) [9], pointing out to the existence 
of a receptor for fibrinogen on the erythro-
cyte membrane, instead of the non-specific 
interaction previously proposed by some 
authors [3].
By performing identical measurements for 
different loading rates and analyzing the 
data with the Bell, Evans and Ritchie for-
malism [12-14], it was possible to obtain 
other parameters characterizing this inter-
action, namely, the energy and width of the 
energy barrier that must be overcome for 
the unbinding to occur, and the dissociation 
rate, or its inverse, the unperturbed bond 
lifetime. The results obtained for this last 
parameter allowed us to conclude that one 
of the reasons why the fibrinogen-erythro-
cyte binding is so difficult to study by more 
conventional methodologies, such as flow 
cytometry, is its reduced lifetime [9].
As it is common for integrins, the αIIbβ3 re-
ceptor for fibrinogen in platelets requires 
calcium to be functional. After the initial ex-
periments, described above, being conduct-
ed in the presence of a physiological con-
centration of Ca2+, new experiments were 
carried out in its absence, additionally add-
ing EDTA to chelate any trace amount that 
could be present. As a first control or proof 
of concept to demonstrate that the interac-
tion measured by force spectroscopy was in 
fact between fibrinogen and the blood cells 
membrane receptor, results obtained in the 
absence of Ca2+ demonstrate, as expected, 
the reduction of the fibrinogen-platelet 
binding, both in terms of force necessary 
to break the bond (decreasing to values 
characteristic of non-specific interactions) 
and of binding frequency [9]. The binding of 
fibrinogen to erythrocytes is also impaired 
by the absence of calcium. This observation 
suggested that the receptor for fibrinogen 
in erythrocytes is also an integrin.
As a second control, or proof of concept, 
we tested the effect of eptifibatide on the 
fibrinogen binding to either of the blood 
cells. This is a cyclic peptide derived from 
barbourin, a component of the venom of 
the southeastern pigmy rattlesnake [15]. It 
Figure 1: Force Spectroscopy technique at an Atomic Force Micros-
cope. (A) Schematic representation of the erythrocytes deposited 
on a poly-L-lysine-coated glass slide and an AFM tip chemically 
functionalized with fibrinogen molecule(s). The arrows represent 
the approach and retraction cycles during the force spectrosco-
py measurements. When approaching the tip to the sample, the 
fibrinogen molecule may contact with cell receptor(s) and the 
binding between them can occur. By retracting the tip away from 
the sample, the binding force necessary to break this bond, at the 
single-molecule level, can be measured. (B) Air tapping-mode AFM 
images of typical circular, biconcave human erythrocytes, from he-
althy blood donors, deposited on poly-L-lysine coated glass slides 
(height 3D image). Reprinted from [10].
Figure 2: Force spectroscopy results from healthy human blood donors in the presence of Ca2+ 1 mM. Rupture-force histograms from about 
8,000 single event-force measurements for the fibrinogen–erythrocyte (red) and fibrinogen-platelet (green) systems. Measurements were 
done with an applied force of 1 nN, pulling speed of 2 μm/s and at a loading rate of 4 nN/s. Reprinted with permission from [9] (© 2010, 
American Chemical Society).
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pathogenic mutation was identified on the 
ITGB3 gene, we could demonstrate that one 
of the two sub-units of the receptor for fi-
brinogen on the erythrocyte membrane is a 
product of the expression of this gene. New 
experiments are being conducted to identify 
the other sub-unit of the receptor.
In parallel, we also evaluated the effect of 
erythrocyte aging on the ability to bind fi-
brinogen [10]. The results indicated that 
upon erythrocytes aging, there was a signif-
icant decrease on the fibrinogen binding, by 
decreasing the frequency of its occurrence 
but not its binding strength. For the bind-
ing between fibrinogen and erythrocytes 
to occur, a lower fibrinogen concentration 
was needed on young erythrocytes than for 
the older ones. We could conclude that the 
fibrinogen-erythrocyte receptor binding can 
be lost, masked or progressively turned to 
non-functional with the in vivo erythrocyte 
senescence process. Knowing that younger 
erythrocytes bind more to fibrinogen, we 
could presume that this population is the 
main responsible for some cardiovascular 
diseases associated with an increase on 
the fibrinogen content in blood, which could 
disturb its normal flow.
2. HIV FUSION INHIBITORS
The infection of a target cell by the human 
immunodeficiency virus type 1 (HIV-1) is me-
diated by the gp120-gp41 viral glycoproteins 
complex (a homotrimer of heterodimers). 
gp120 binds to the cell receptor CD4 and 
to a co-receptor, usually CCR5 or CXCR4 
[18]. After these bindings, gp41 is exposed, 
acquiring an extended conformation and 
enabling the insertion of its fusion peptide 
in the target cell membrane. Subsequent-
ly, another conformational change takes 
place, in which two heptad repeat domains 
of each of the three gp41 monomers come 
together, forming a structure named six-
helix bundle. It brings the viral and cell 
membranes together, enabling the forma-
tion of the fusion pore and the entrance of 
the viral content into the cell [19] (Figure 3).
HIV fusion inhibitor peptides were initially 
designed with a sequence corresponding 
to one of the heptad repeat domains, in 
order to inhibit the binding to the opposite 
heptad repeat domain of gp41, impairing 
the six-helix bundle formation and, there-
fore, the entry of the viral content into the 
target cell [20]. Experimental evidences 
showed that this is, at least, a partial ex-
planation, as inhibitors with a higher bind-
ing to the gp41 heptad repeat domain were 
shown to be ineffective in vivo, while some 
peptides with a lower binding to gp41 are 
efficient [21].
The peptides enfuvirtide (T-20) and T-1249 
are two of these HIV fusion inhibitors. Enfu-
virtide is the only fusion inhibitor approved 
so far for clinical use. Its sequence corre-
sponds to part of the HIV gp41 C-terminal 
is considered to be a specific inhibitor of the 
αIIbβ3 integrin, used in hospital settings to 
treat platelet hyperaggregation. As expect-
ed, eptifibatide inhibited fibrinogen-platelet 
binding at the extension and concentra-
tions range expected based on the clinical 
studies [15, 16]. Regarding the binding to 
erythrocytes, eptifibatide also inhibited the 
binding of fibrinogen. However, the same 
threshold level of inhibition observed for 
platelets was reached only at higher epti-
fibatide concentrations [9]. This indicates 
that the receptor for fibrinogen on eryth-
rocytes is not the glycoprotein αIIbβ3, but an 
αIIbβ3-related integrin.
All the results described so far were obtained 
using blood samples from healthy volunteer 
blood donors. As a third and final control or 
proof of concept, identical measurements 
were carried out with cells isolated from a 
blood sample of a patient with Glanzmann 
thrombasthenia. This is a rare hereditary 
disease which patients have impaired co-
agulation due to the absence of the αIIbβ3 
receptor or its presence on a non-functional 
mutated form [17]. Expectedly, tapping with 
the fibrinogen-derivatized tip on platelets 
from this patient almost yielded no binding. 
On the few situations in which the binding 
occurred, the force necessary to break the 
bond was rather low, characteristic of non-
specific interactions. Performing identical 
measurements with erythrocytes, we could 
demonstrate for the first time that Glanz-
mann thrombasthenia patients can also have 
impaired fibrinogen-erythrocyte binding [9]. 
Genetic studies were conducted to identify if 
the mutation responsible for the Glanzmann 
thrombasthenia in this patient was on the IT-
GA2B or on the ITGB3 gene (responsible for 
the expression of the αIIb and β3 sub-units of 
the platelet receptor, respectively). As the 
Figure 3: Steps required for HIV-1 glycoprotein mediated membrane fusion with the host cells, as explained in the main text. A fusion inhibitor 
peptide (e.g., enfuvirtide and T-1249) may block the formation of the six-helix bundle, preventing the fusion of the viral and cell membranes. 
Reprinted with permission from [45] (© 2000, Cold Spring Harbor Laboratory Press).
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heptad repeat domain. T-1249 is a second 
generation drug, with successful prelimi-
nary clinical results, which development is 
presently on hold. Its sequence includes 
elements from fusion proteins of HIV-1, 
HIV-2 and SIV (simian immunodeficiency 
virus). In a line of work developed together 
with Miguel Castanho’s group (formerly at 
the Faculty of Sciences of the University 
of Lisbon, and now also at the Institute 
of Molecular Medicine (IMM) / Faculty of 
Medicine of the University of Lisbon), we 
have used the intrinsic fluorescence of the 
tryptophan residues in both peptides to 
study their interaction with biomembrane 
model systems (lipid vesicles) [22, 23]. In 
these studies, we showed that enfuvirtide 
and T-1249 partition to fluid phase lipid 
membranes, and that T-1249 (but not enfu-
virtide) additionally adsorbs to the surface 
of cholesterol rich membrane domains.
Recently, we extend these observations to 
the interaction of enfuvirtide and T-1249 
with biological membranes, using human 
PBMC (peripheral blood mononuclear 
cells) and erythrocytes [24]. PBMC were 
chosen because they include one of the 
main targets for HIV infection: CD4+ T-lym-
phocytes. Erythrocytes are not infected by 
HIV. However, it is found in vivo bound to 
the erythrocyte membrane, constituting 
a significant reservoir of infective viruses, 
even during highly active antiretroviral 
therapy (HAART) [25, 26].
To study the interaction of the peptides 
with the cell membranes, we could not 
use the same methodology as on the pre-
vious studies with biomembrane model 
systems (changes on peptide fluorescence 
properties upon membrane insertion 
[27]), as the fluorescence of the peptides 
would be masked by the fluorescence of 
the innumerous aromatic amino acid resi-
dues of the different protein components 
of the cells. Therefore, a new strategy 
had to be used: Instead of looking at the 
fluorescence of the peptide itself, we fol-
lowed the changes induced by the pep-
tide on the fluorescence of a membrane 
probe sensitive to the membrane potential 
[28]. After testing different fluorescent 
probes, we choose to use di-8-ANEPPS 
(4-[2-[6-(dioctylamino)-2-naphthalenyl]
ethenyl]-1-(3-sulfopropyl)-pyridinium) for 
that purpose. The fluorescence of di-8-
ANEPPS is highly sensitive to the mem-
brane dipole potential, with an increase 
on this potential leading to a blue-shift 
on the probe excitation spectra. Quantita-
tively, the variations of the membrane di-
pole potential are easier to assess using 
as experimental output the ratio between 
the values obtained at two wavelengths of 
the fluorescence difference spectrum (ob-
tained subtracting the spectrum without 
peptide from the spectrum obtained for a 
given concentration of the peptide).
di-8-ANEPPS was shown by confocal mi-
croscopy to properly label the cell mem-
branes of PBMC and erythrocytes [24]. By 
adding enfuvirtide or T-1249 to the labeled 
cells, the shape of the difference spectra 
revealed concentration-dependent shifts 
to the red, indicative of a decrease in 
membrane dipole potential upon the bind-
ing of these peptides. The quantitative val-
ues allowed the calculation of the peptide-
cell dissociation constants [24]. This way, 
both peptides were shown to interact with 
erythrocyte and lymphocyte membranes. 
There is a complete agreement between 
these results and the data previously ob-
tained with biomembrane model systems 
[22, 23]. T-1249 has an affinity for these 
blood cells approximately eight-fold high-
er than enfuvirtide (Figure 4). This can be 
related with its higher partition constant 
and with the ability to adsorb to choles-
terol-rich membrane domains, probably 
contributing for its improved antiretroviral 
efficacy [22].
In order to close the gap between the re-
sults obtained with biomembrane model 
systems, using the peptides intrinsic tryp-
tophan fluorescence, and those obtained 
with blood cells, based on di-8-ANEPPS 
fluorescence, we also performed experi-
ments using di-8-ANEPPS-labelled lipid 
vesicles, with different membrane com-
positions. The results were in agreement 
with the expected, with the addition of 
cholesterol to fluid phase lipid vesicles 
leading to a decrease on the enfuvirtide-
membrane binding and to an increase on 
the binding of T-1249 [24].
Based on our findings, we proposed a 
model in which the HIV-1 association with 
erythrocytes in vivo could constitute a route 
to deliver peptide to the viral membranes 
(Figure 5). This should be especially rel-
Figure 4: Peptide affinity towards erythrocytes and PBMC cell membranes. The plots represent the dependence of the ratio on the enfuvirtide 
(red) and T-1249 (blue) concentrations for erythrocytes (A) and PBMC (B), the dashed curves are fittings to a single binding site model. Ratio 
values were normalized for the initial value of zero peptide concentration. Plotted values represent the mean ± standard error of mean (error 
bars not visible for erythrocytes due to small errors). N = 6 for erythrocytes and N = 7 for PBMC. Reprinted from [24].
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evant for T-1249, as the viral membrane 
is rich in cholesterol [29]. Regarding lym-
phocytes, their membrane can concentrate 
and accelerate the drug interactions with 
its molecular target, gp41 in its exposed 
conformation. The local enrichment of the 
inhibitor at the membrane level would in-
crease the probability of taking advantage 
of the narrow spatial and time window dur-
ing which gp41 is in the extended confor-
mation in order to bind to it.
Going against the “textbook dogma” that 
the membrane fusion step of HIV-1 infec-
tion occurs at the surface of the cell, the 
group of Gregory Melikian published in 
2009 a study with compelling evidences 
for an entry of HIV-1 via endocytosis [30]. 
Subsequent evidences additionally sup-
ported this theory [31]. If this is true, the 
relevance of the membrane binding of HIV 
fusion inhibitors is further strengthened, 
as a possible endocytic entry pathway 
would protect HIV from a fusion inhibi-
tor only present in solution. However, its 
membrane binding and enrichment would 
drastically increase the inhibitory efficacy, 
by assuring a significant concentration to 
be present at the endosome level, where 
membrane fusion would occur.
Recently, the same experimental approach 
was also used for sifuvirtide, another sec-
ond generation HIV fusion inhibitor that 
successfully completed phase IIb clinical 
trials in 2010 [32].
3. rBPI21 MOLECULAR LEVEL MECHANISM 
OF ACTION
Section 1 was dedicated to an AFM-based 
force microscopy approach to a specific 
subject. Section 2 describes the use of fluo-
rescence spectroscopy to address another 
one. Finally, in Section 3 another line of 
work ongoing at the Biomembranes Unit of 
IMM will be described; namely, the study of 
the mechanism of action of the antimicro-
bial protein rBPI21, addressed by a different 
methodology: light scattering spectroscopy.
Gram-negative bacteria have two mem-
branes, separated by a peptidoglycan 
layer. The outer leaflet of their outer mem-
brane is constituted mainly of lipopolysac-
charide (LPS). Both the inner membrane 
and the inner leaflet of the outer mem-
brane do not present LPS, having in their 
content high proportions of negative phos-
pholipids, such as phosphatidylglycerol 
(PG). LPS is also negatively charged. Upon 
infection by Gram-negative bacteria, it is 
the causative agent of sepsis. At high con-
centrations, LPS may lead to septic shock 
and, eventually, to death [33].
Our organism has two structurally similar 
proteins that bind LPS: the LPS-binding 
protein (LBP) and the bactericidal/perme-
ability-increasing protein (BPI). Despite 
the structural similarity, their binding to 
LPS leads to opposite outcomes: The bind-
ing of LBP to LPS enables the activation 
of the inflammatory cascade, through the 
binding to CD14 [34]. On the contrary, the 
binding of BPI to LPS allows its neutrali-
zation and clearance, together with the 
blocking of the inflammatory cascade [34]. 
BPI is produced by neutrophils. It exerts 
its antibacterial activity both intracellu-
larly (at the azurophil or primary granules 
of the neutrophil) and extracellularly (re-
lease of antimicrobial peptides and pro-
teins from the specific or secondary gran-
ules during neutrophil activation). This 
protein has a boomerang-like shape, with 
a cationic N-terminal domain, responsible 
for the antimicrobial activity and LPS neu-
tralization, and with the C-terminal being 
responsible for cell-recognition [35, 36]. 
rBPI21 was designed with the sequence 
of the 193 amino acid residues of the N-
terminal of BPI, except for the change of a 
cysteine for an alanine [37].
To study the mechanism of action of rBPI21, 
we used mainly dynamic light scattering 
(DLS) and zeta-potential measurements 
[38, 39]. DLS spectroscopy is based on the 
evaluation of the Brownian motion of the 
scattering particle, in order to obtain its dif-
fusion coefficient and, based on it, to cal-
culate the hydrodynamic radius or diameter 
of the particle using the Stokes-Einstein 
equation. Zeta-potential is a parameter 
that can be used to evaluate the electro-
static interaction between particles and 
Figure 5: Proposed mode of action of enfuvirtide and T-1249 in circulation with blood cells. Reprinted from [24].
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to give information on the stability of col-
loidal dispersions. Most of the particles in 
aqueous solution carry an electric charge 
and this charge influences the distribu-
tion of the ions at the particle surface. The 
counterions attached to the particle cre-
ate an electrical double layer, with an in-
ner region (Stern layer), where the ions are 
firmly attached, and an outer layer, where 
the ions diffuse more freely. In this diffuse 
layer, there is a boundary where ions and 
particle inside it form a stable entity. Dur-
ing the zeta-potential measurements, an 
electric field is superimposed to the ran-
dom Brownian motion. When a scattering 
particle is moving, ions within the bound-
ary region move with the particle. The zeta-
potential is defined as the potential created 
at this boundary [38].
In this study, we started by following the 
changes on the size and zeta-potential of 
the LPS aggregates naturally formed in so-
lution [40]. Upon their titration with rBPI21, 
there was a marked increase of the hydro-
dynamic diameter of the aggregates, with 
the size distribution becoming bimodal 
above a threshold level of the [rBPI21]/[LPS] 
ratio. The zeta-potential of the LPS aggre-
gates (in the absence of rBPI21) is highly 
negative. With the addition of rBPI21, it pro-
gressively increases, leveling up at positive 
zeta-potential values.
The interaction of rBPI21 with biomembrane 
model systems (large unilamellar vesicles; 
LUV) with different lipid compositions was 
also addressed [40, 41], including systems 
containing LPS and/or POPG (palmitoy-
loleoylphosphatidylglycerol), in order to 
mimetize Gram-negative bacteria mem-
branes. On previous studies, we partici-
pated on the development of spectroscopi-
cal methodologies to quantify the partition 
constant (Kp) of a given molecule between 
the aqueous phase and membranes (for 
reviews see, [27, 42, 43]). Based on the 
changes on the intrinsic fluorescence of the 
tryptophan residues of rBPI21 upon mem-
brane binding (followed by fluorescence 
spectroscopy), we measured its partition to 
membranes of different lipid compositions, 
and verified that high partitions to mem-
branes occurred not only to LPS-containing 
systems, but also to membranes containing 
negative phospholipids, such as POPG [41]. 
By the opposite, no significant partition was 
observed for LUV made exclusively of zwit-
terionic (neutral) phospholipids, such as 
POPC (palmitoyloleoylphosphatidylcholine).
By using DLS to assess the lipid vesicles 
size variations induced by the presence 
of increasing concentrations of rBPI21, we 
realized that extensive aggregation was 
induced in the presence of POPG in the 
membranes, but not by the presence of 
LPS or POPC (Figure 6) [40]. Zeta-potential 
measurements shown that there is a higher 
affinity of rBPI21 for POPC:POPG mixtures, 
relative to pure POPG (Figure 7). Therefore, 
the rBPI21 interaction with membranes is 
not purely electrostatic.
To complement the DLS and zeta-potential 
studies, two other types of measurements 
were conducted, namely, membrane fusion 
and membrane leakage assays, in order to 
evaluate if these processes are promoted by 
rBPI21 [40]. For the membrane fusion (lipid 
mixing) assay, we used a Förster resonance 
energy transfer (FRET; see Fernandes et al. 
in this Canal BQ issue) methodology, with 
nitro-2-1,3-benzoxadiazol-4-yl-dipalmi-
toylphosphatidylehtanolamine (NBD-PE) 
as donor and sulforhodamine B-dipalmi-
toylphosphatidylehtanolamine (RhB-PE) as 
acceptor. One-fourth of the LUV used for 
the assay was labeled with both fluorescent 
membrane probes, while the remaining li-
pid vesicles were unlabeled. The fusion ef-
ficiency could be calculated based on the 
decrease of the energy transfer between 
both probes, as the fusion between labeled 
and unlabeled vesicles increases the aver-
age distance between the two probes (sur-
face dilution effect). With this assay, we ob-
served that the rBPI21-induced membrane 
fusion (tested with increasing concentra-
tions of the protein) is promoted by the 
presence of POPG, but not by the presence 
of LPS or POPC.
For the membrane leakage assay, we used 
LUV with carboxyfluorescein entrapped on 
their lumen. This fluorescent probe, when 
at high concentrations, undergoes a fluo-
rescence self-quenching effect. Thus, the 
quantification is made by adding the protein 
and registering the eventual increase of the 
carboxyfluorescein fluorescence due to its 
dilution upon leakage. In order to obtain 
a reference value, total leakage was pro-
moted afterwards by adding triton X-100. 
The results showed that rBPI21 promotes 
membrane leakage as long as the lipid 
membrane contains either POPG or LPS.
Figure 6: Aggregation of LUV caused by rBPI21. Hydrodynamic dia-
meter variation of lipid vesicles with increasing rBPI21 concentra-
tion. Bars represents the size range from three independent ex-
periments. Larger ranges are intrinsically associated to vesicles 
flocculation/precipitation (marked *). POPC (black); POPG (blue); 
POPC:POPG 55:45 (orange); POPC:POPG 80:20 (green); POPC:LPS 
80:20 (red); POPC:POPG:LPS 60:20:20 (brown). Reprinted from [40].
Figure 7: Zeta-potential for membrane model systems in the 
presence of rBPI21. Bars represent the zeta-potential range 
from at least two independent experiments. POPC (black); 
POPG (blue); POPC:POPG 55:45 (orange); POPC:POPG 80:20 
(green); POPC:LPS 80:20 (red); POPC:POPG:LPS 60:20:20 
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